Navigation Links
New Phase II study shows first-line promise of lung cancer drug PF-299
Date:10/12/2010

A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).

Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong.

While some existing drugs reversibly inhibit the cancer-linked receptor HER-1 (also known as EGFR), PF-299 is a 'pan-HER' inhibitor, which irreversibly inhibits several members of the HER family, including EGFR, HER-2 and HER-4.

"We know that PF-299 is a different compound than drugs such as erlotinib and gefitinib, targeting multiple receptors on the HER pathway," Dr Mok said. "We also know from preclinical work that PF-299 inhibits signaling in both wild-type and mutant EGFR, including forms of NSCLC that are resistant to EGFR inhibitors such as erlotinib and gefitinib."

The current trial includes patients with advanced non-small cell lung cancer and no prior systemic treatment for their disease. All were either non-smokers or light smokers, or were known to have EGFR mutations.

So far, 74 of 80 planned patients have enrolled. Of the 41 with known EGFR status, 27 had activating mutations.

Each patient was administered either 30mg or 45mg of PF-299 once daily, and were assessed every 28 days. After 9 months of treatment, 57.1% of patients overall, and 84.7% of those patients with EGFR mutations, remained progression-free, Dr Mok reported. The expected median progression-free survival with standard-of-care chemotherapy in this patient population is approximately six months.

"Even though these data are preliminary and patients are still being f
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 The report “Sinusitis ... analysis on the therapeutic development for Sinusitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Sinusitis ...
(Date:4/21/2015)... April 21, 2015 Wireless Analytics, ... has been recognized by the Boston Business Journal as ... ranking was announced at a recent event celebrating the ... of the fastest-growing private companies in Massachusetts. , Wireless ... the state that recorded the fastest revenue growth from ...
(Date:4/21/2015)... April 21, 2015 QuickMedical, a ... and supplies, now represents Schiller America's ... ECGs, Stress Tests, and Vital Signs Monitors, among ... Switzerland, is a global leader in the development ... are developed in close cooperation with the world's ...
(Date:4/21/2015)... San Diego, CA (PRWEB) April 21, 2015 ... Deconstructed PACS® strategy , Visage Imaging ... Ltd. (ASX: PME), has signed a seven-year contract ... health system in Northern Florida. The deal furthers ... the university/academic hospital space, a key area of the ...
(Date:4/21/2015)... Baltimore, Maryland (PRWEB) April 21, 2015 ... air, according to the U.S. Environmental Protection Agency (EPA). ... UV rays and cigarette smoke increase the level of ... help the body eliminate these harmful toxins is to ... superfood, broccoli boasts the highest level of glucoraphanin – ...
Breaking Medicine News(10 mins):Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 3
... governments, including California as well as others in Canada ... taxpayer dollars into major motion pictures that depict smoking ... year, a University of California, San Francisco (UCSF) researcher ... PLoS Medicine , those subsidies, along with government ...
... Aug. 23 (HealthDay News) -- Researchers say boys are ... that males have been reaching sexual maturity about 2.5 ... "The reason for earlier maturity for ... disease environments are getting more favorable for it," demographer ...
... By Amanda Gardner HealthDay Reporter , ... are hospitalized fail to receive their regular medications for ... restart them when they,re discharged, researchers say. Patients ... less likely to resume their regular medication schedule after ...
... Aug. 23 (HealthDay News) -- Certain types of mental illnesses ... indicates. Men are more likely to be diagnosed with ... to develop anxiety or depression, according to the researchers. ... efforts, said the study authors, who analyzed data collected in ...
... of Nottingham are to investigate whether the therapeutic effects ... their feelings of anger, anxiety and depression. Academics ... Contemporary art gallery and local artists for the innovative ... clay could offer to young people struggling with mental ...
... (HealthDay News) -- The amount of fighting and arguing in ... a new study suggests. Ohio State University researchers looked ... 1980 to 2000. Based on how often participants said they ... middle- and high-conflict marriages. There was little change in ...
Cached Medicine News:Health News:Taxpayer film subsidies promote youth smoking 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 3Health News:Mental Illness Affects Women, Men Differently, Study Finds 2Health News:Modelling emotions: A potential new therapy for disturbed teenagers 2Health News:Modelling emotions: A potential new therapy for disturbed teenagers 3Health News:Couples Who Don't Fight Much Aren't Likely to Start 2
(Date:4/21/2015)... 2015 Global cap & closure ... for caps and closures will exceed $55 billion in 2019. ... trillion annually. Beverages will continue to account for well over ... number of smaller markets are expected to register faster growth. ... the most developed markets -- the US, Western ...
(Date:4/21/2015)... Fla. , April 21, 2015  A new, ... the First Coast that promises to revolutionize the way ... fellowship-trained at the world-renowned Montsouris Institute in ... guided prostate biopsy in the North Florida ... this innovative technology in prostate cancer diagnosis and management ...
(Date:4/21/2015)... SARASOTA, Fla. , April 21, 2015   ... a drug development company focused on the treatment of ... a key independent appointment to the Company,s Board of ... Chundru Samuel as a new director. ... CEO of Rock Creek Pharmaceuticals, said, "Dr. Samuel,s experience ...
Breaking Medicine Technology:World Caps & Closures Market 2World Caps & Closures Market 3Kasraeian Urology Unveils Jacksonville's First UroNav Advanced Prostate Cancer Detection Technology 2Kasraeian Urology Unveils Jacksonville's First UroNav Advanced Prostate Cancer Detection Technology 3Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 2Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 3Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 4Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 5Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 6Rock Creek Pharmaceuticals Appoints New Director and Provides Notice of Settlement of Derivative Litigation 7
... Combination gives you the freedom ... enhanced by distributing 70% of ... hips leaving only 30% of ... shoulders. Freedom of movement enhanced ...
A simple, one-piece design eliminates seams that irritate and also extend the life of the collar. Comes with extra long Velcro closure to fit all. Also available with trim. One size fits all. Availab...
The maternity apron is a very critical protection device for the patient and the fetus....
... Special Protective Apron is made to ... a sterile gown. Uniquely it can ... field. Reaching through the back of ... released, and the protective apron will ...
Medicine Products: